

License No.	Name/Address	Date reissued
2849F	Amex International, Inc., 1615 L Street, NW., Suite 340, Washington, DC 20036.	March 5, 2000.

Sandra L. Kusumoto,

Director, Bureau of Consumer Complaints and Licensing

[FR Doc. 01-7032 Filed 3-20-01; 8:45 am]

BILLING CODE 6730-01-P

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Additional information on all bank holding companies may be obtained from the National Information Center website at www.ffiec.gov/nic/.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than April 13, 2001.

Federal Reserve Bank of Chicago
(Phillip Jackson, Applications Officer)
230 South LaSalle Street, Chicago,
Illinois 60690-1414:

1. *Peotone Bancorp, Inc.*, Peotone, Illinois; to acquire 20.62 percent of the voting shares of SouthwestUSA Corporation, Las Vegas, Nevada, and thereby indirectly acquire

SouthwestUSA Bank, Las Vegas, Nevada.

Board of Governors of the Federal Reserve System, March 15, 2001.

Robert deV. Frierson

Associate Secretary of the Board.

[FR Doc. 01-6942 Filed 3-20-01; 8:45 am]

BILLING CODE 6210-01-S

FEDERAL RESERVE SYSTEM

Sunshine Act Meeting

Agency Holding the Meeting: Board of Governors of the Federal Reserve System.

Time and Date: 10:00 a.m., Monday, March 26, 2001.

Place: Marriner S. Eccles Federal Reserve Board Building, 20th and C Streets, N.W., Washington, D.C. 20551.

Status: Closed.

Matters to be Considered:

1. Personnel actions (appointments, promotions, assignments, reassignments, and salary actions) involving individual Federal Reserve System employees.

2. Any items carried forward from a previously announced meeting.

Contact Person for More Information: Lynn S. Fox, Assistant to the Board; 202-452-3204.

SUPPLEMENTARY INFORMATION: You may call 202-452-3206 beginning at approximately 5 p.m. two business days before the meeting for a recorded announcement of bank and bank holding company applications scheduled for the meeting; or you may contact the Board's Web site at <http://www.federalreserve.gov> for an electronic announcement that not only lists applications, but also indicates procedural and other information about the meeting.

Dated: March 16, 2001.

Robert deV. Frierson,

Associate Secretary of the Board.

[FR Doc. 01-7085 Filed 3-16-01; 4:34 pm]

BILLING CODE 6210-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

National Institute for Occupational Safety and Health Announcement of Public Meeting to Discuss Potential Standards or Guidelines for Respiratory Protective Devices Used to Protect Emergency Response Workers Against Chemical, Biological, and Radiological Agents

AGENCY: Centers for Disease Control and Prevention (CDC), National Institute for Occupational Safety and Health (NIOSH), Department of Health and Human Services (DHHS).

ACTION: Notice of a public stakeholder meeting to discuss the Agencies' current understanding of threats in responding to chemical, biological, and radiological incidents, user needs, and potential standards or guidelines for respiratory protective devices suitable for use by first responders.

DATES: 9 a.m.-5 p.m. April 17, 2001; 9 a.m.-5 p.m. April 18, 2001.

Location: Building E4810, U.S. Army Soldier and Biological Chemical Command, Edgewood Chemical Biological Center, Edgewood Area, Aberdeen Proving Ground, MD 21010-5424.

This meeting is hosted by NIOSH, the National Institute for Standards and Technology (NIST), and the U.S. Army Soldier and Biological Chemical Command (SBCCOM).

The meeting will be open to the public, limited only by the space available.

The meeting room accommodates approximately 220 people.

Requests to make presentations at the public meeting should be mailed to the NIOSH Docket Officer, Robert A. Taft Laboratories, M/S C34, 4676 Columbia Parkway, Cincinnati, Ohio 45226, telephone 513/533-8450, fax 513/533-8230, or e-mailed to NIOCINDOCKET@CDC.GOV on or before April 6, 2001. All requests to present should contain the name, address, and telephone number, relevant business affiliations of the presenter, a brief summary of the presentation, and the approximate time requested for the presentation. Oral

presentations should be limited to 15 minutes.

The purpose of the meeting is to obtain comments from individuals regarding potential chemical and biological respiratory protection standards and guidelines that NIOSH is developing in collaboration with SBCCOM and NIST.

After reviewing the requests for presentations, NIOSH will notify each presenter by mail or telephone of the approximate time that his or her oral presentation is scheduled to begin. If a participant is not present when his or her presentation is scheduled to begin, the remaining participants will be heard in order. At the conclusion of the meeting, an attempt will be made to allow presentations by any scheduled participants who missed their assigned times. Attendees who wish to speak but did not submit a request for the opportunity to make presentations may be given this opportunity at the conclusion of the meeting, at the discretion of the presiding officer.

SUMMARY: The Agencies will provide information to attendees concerning the progress of their collaborative efforts and their current understanding of chemical, biological, and radiological respiratory protection issues including threats or hazards, and the developmental status of chemical and biological standards and guidelines. Participants will be given an opportunity to ask questions of Agencies' representatives, and to present individual comments that they wish to have considered.

Background

Due to the recognition that terrorism is a national domestic security issue, municipal, state, and national guard responder groups, particularly those in locations considered potential targets, have been developing response and consequence management plans. The federal Interagency Board for Equipment Standardization and Interoperability (IAB) has worked to identify personal protective equipment that is already available on the market for responders' use. The IAB has identified the development of standards or guidelines for respiratory protection equipment as a top priority. NIOSH, NIST, National Fire Protection Association and the Occupational Safety and Health Administration have entered into a Memorandum of Understanding defining each agency or organization's role in developing, establishing and enforcing standards or guidelines for responders' respiratory protective devices. NIST has initiated Interagency Agreements with NIOSH and SBCCOM

to aid in the development of appropriate respiratory protection standards or guidelines. NIOSH has the lead in developing standards or guidelines to test, evaluate and approve respirators.

Specific Discussion and Comment Topics

NIOSH, SBCCOM, and NIST are holding this meeting to present their progress in assessing respiratory protection needs of responders to chemical, biological, and radiological incidents. The Agencies will present their methods or models for developing hazard and exposure estimates, and their status in evaluating test methods and performance standards that may be applicable as future chemical and biological respirator standards or guidelines. Participants are invited to provide their individual comments on these topics and to identify additional information that will help in developing respiratory standards and guidelines.

The Agencies have evaluated threat and vulnerability assessments and other associated documents to gain understanding of probable terrorism agents including chemical warfare agents, biological warfare agents, and toxic industrial materials. A summary of the findings will be presented at the meeting for discussion and comment by the attendees.

There are multiple classes of respirators having various operational parameters. The Agencies are currently aware that the domestic preparedness community is purchasing self-contained breathing apparatus (SCBA), and full facepiece powered and non-powered air-purifying respirators to equip response teams for which there are no NIOSH chemical/biological respirator approval standards. NIOSH and SBCCOM are in the process of developing chemical and biological respiratory protection standards and guidelines, and will present pertinent information for each class of respirator. The Agencies will discuss potential tests and test parameters being considered for each respirator class.

For SCBA, the parameters are system and component agent permeation testing and laboratory protection level testing. For air-purifying respirators, the same parameters are being considered plus challenge concentrations, breakthrough and end-point concentrations, breathing flow rates, hot and cold temperature function, human wear factors, assessment of current respirator technologies, etc. The status of NIOSH and SBCCOM in these efforts will be presented at the meeting. Participants are invited to provide individual comment on these and other

performance, quality, or operational parameters that should be considered.

Comments on the topics presented in this notice should be mailed to the NIOSH Docket Office, Robert A. Taft Laboratories, M/S C34, 4676 Columbia Parkway, Cincinnati, Ohio 45226, telephone 513-533-8450, fax 513/533-8230. Comments may also be submitted by e-mail to: NIOCINDOCKET@CDC.GOV. E-mail attachments should be formatted as WordPerfect 6/7/8/9, or Microsoft Word. Comments should be submitted to NIOSH no later than May 31, 2001, and should reference docket number, NIOSH-002, in the subject heading.

FOR FURTHER INFORMATION CONTACT: John M. Dower or Ray Wells, NIOSH, 1095 Willowdale Road, Morgantown, West Virginia 26505-2888, telephone 304/285-5907, fax 304/285-6030 and/or Email: respcert@cdc.gov. or Mr. Wayne Davis, Product Director for Respiratory Protection, Project Manager for Nuclear, Biological and Chemical Defense Systems, SBCCOM, 5183 Blackhawk Road, Aberdeen Proving Ground, MD 21010-5424, ATTN: AMSSB-PM-RNN-P/ Mr. Wayne Davis, telephone 410 436-1776, fax 410 436-4185 and/or Wayne.davis@sbccom.apgea.army.mil.

The Director, Management Analysis and Services office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: March 15, 2001.

John Burckhardt,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 01-6977 Filed 3-20-01; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 01D-0086]

Draft Guidance for Industry: Disclosing Information Provided to Advisory Committees in Connection With Open Advisory Committee Meetings Related to the Testing or Approval of Biologic Products and Convened by the Center for Biologics Evaluation and Research; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.